Clozapine-induced gastroesophageal rumination in 22q11.2 Deletion Syndrome. A case report on gastroesophageal side effects management without renouncing clozapine's effectiveness.

Accinni, Tommaso; Frascarelli, Marianna; Ghezzi, Francesco; Panzera, Alessia; Buzzanca, Antonino; Fanella, Martina; Di Bonaventura, Carlo; Carlone, Luca; Girardi, Nicoletta; Pasquini, Massimo; Di Fabio, Fabio

Accinni, Tommaso; Frascarelli, Marianna; Ghezzi, Francesco; Panzera, Alessia; Buzzanca, Antonino; Fanella, Martina; Di Bonaventura, Carlo; Carlone, Luca; Girardi, Nicoletta; Pasquini, Massimo; Di Fabio, Fabio.

Afiliação

Accinni T; Department of Human Neurosciences Sapienza University Rome Italy.
Frascarelli M; Department of Human Neurosciences Sapienza University Rome Italy.
Ghezzi F; Department of Human Neurosciences Sapienza University Rome Italy.
Panzera A; Department of Human Neurosciences Sapienza University Rome Italy.
Buzzanca A; Department of Human Neurosciences Sapienza University Rome Italy.
Fanella M; Department of Human Neurosciences Sapienza University Rome Italy.
Di Bonaventura C; Department of Human Neurosciences Sapienza University Rome Italy.
Carlone L; Department of Human Neurosciences Sapienza University Rome Italy.
Girardi N; Department of Human Neurosciences Sapienza University Rome Italy.
Pasquini M; Department of Human Neurosciences Sapienza University Rome Italy.
Di Fabio F; Department of Human Neurosciences Sapienza University Rome Italy.

Clin Case Rep ; 9(5): e04134, 2021 May.

Article em En | MEDLINE | ID: mdl-34084508

RESUMO

Despite entailing more severe and uncommon side effects in 22q11.2DS compared to idiopathic schizophrenia, we strongly believe that clozapine should continue to be considered the gold standard for all treatment-resistant schizophrenia, even in 22qDS.

Palavras-chave

genetics; pharmacology; psychiatry

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google